- About the Lecture
-
About the Lecture
Recent scrutiny of the pharmaceutical industry -- brought into sharp focus by Merck’s Vioxx trial -- is leading to some big changes in the development and marketing of drugs. This panel shares deep concerns about the direction of public opinion and policy. Una Ryan’s company has cooked up cost-effective vaccines that may help prevent and treat common diseases, and which can be administered orally, with a single dose, delivering quick protection. Now, new rules may demand more elaborate testing before her drugs come to market, says Ryan, with potential clinical trials running up to half a billion dollars. She says, “If we’re going to have to go through ridiculous and onerous regulatory cycles, we won’t be able to sell at low prices.”
Robert Spiegel wonders if the new regulatory environment will continue to allow drug makers to “take chances early, and make investments taking large risks?” If the movement is “toward zero tolerance toward drug safety, and there’s a frenzy to get rid of drugs with some safety issue,” then the whole economic model of the industry is in peril, he says.
Robert Tepper outlines the new, “post-Vioxx” pattern, “where regulators say the job of the company is to begin risk management from the lab. As soon as we see some side effect, we must build that into our development program so we understand how it plays out.” This means drawing up long-term plans involving follow-up studies and registries of every patient starting the drug. “My plea, says Tepper, is “to keep this flexible…based on science and feasibility.”
John Fallon worries that health plans like his will be playing catch-up to build electronic medical databases and physician-supported tools to help monitor drug reactions in large populations. Employer groups, already unhappy with the costs of health care, are now “saying to health plans…where were you when Vioxx got into trouble?”
Ernst Berndt notes that with new FDA standards involving drug surveillance, “IT and engineering are becoming an important part of the drug evaluation and monitoring process,” which will mean not only that databases must be standardized nationally, but internationally as well.
Related Videos
-
Innovation in Post-Launch Surveillance and Pharmaco-Vigilance
(Part Two)Névine Zariffa, John Glaser, Randall Lutter and Joanna Haas
August 18, 2005
-
Innovation in Manufacturing and Distribution Systems (Part Three)
Mark Bamforth, Peter Walsh, Abbot Weiss and Daniel Engels
August 18, 2005
-
Challenges to Implementation
Gareth Williams, Gary Cooper and Yuri Dikhanov
August 12, 2004
-
- About the Speakers
-
About the Speakers
Moderator: Frank L. Douglas
Executive Director, MIT Center for Biomedical Innovation
Professor of the PracticeFrank L. Douglas has earned many honors, including the Chief Scientific Officer of the Year, Pharmaceutical Achievement Awards, 2004; and the Medal of Honor, Johann Wolfgang von Goethe, University of Frankfurt, 2004.
His research focuses on innovative methodologies in therapeutics, diagnostics and devices. He received his M.S. and Ph.D. in Physical Chemistry from Cornell University, and an M.D. from Cornell University Medical College in 1977.Una Ryan
President & CEO, AVANT Immunotherapeutics, Inc. Chair, Massachusetts Biotechnology Council Director, Biotechnology Industry Organization
Robert J. Spiegel
Senior Vice President, Medical Affairs and Chief Medical Officer, Schering-Plough Research Institute
Robert Tepper
President, Research and Development
Millennium PharmaceuticalsJohn A. Fallon
Chief Physician Executive and Senior Vice President, Blue Cross Blue Shield of Massachusetts
Ernst R. Berndt
Louis B. Seley Professor of Applied Economics, MIT Sloan School of Management
- About the Host
-
About the Host
MIT Center for Biomedical Innovation
Video Player
Defining the Challenges Surrounding Innovation and Safety (Part One)
- Moderator: Frank L. Douglas
- Una Ryan
Robert J. Spiegel
Robert Tepper
John A. Fallon
Ernst R. Berndt - August 18, 2005
- Running Time: 1:31:06
Host
Series
Event Co-Sponsors
